Newsroom

Press Release - All

• 21 Oct 2021
  Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
• 13 Oct 2021
  Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
• 28 Sep 2021
  Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)
• 23 Sep 2021
  Dr. Mikael Dolsten Named to Agilent Board of Directors
• 22 Sep 2021
  Agilent Announces Cash Dividend of 19.4 Cents per Share
• 07 Sep 2021
  Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute
• 02 Sep 2021
  Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
• 01 Sep 2021
  Agilent to Present at Wells Fargo Virtual Healthcare Conference
• 23 Aug 2021
  Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer
• 19 Aug 2021
  Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer